A retrospective study comparing the effectiveness and toxicity of radiotherapy combined with nimotuzumab and chemoradiotherapy in patients with locally recurrent nasopharyngeal carcinoma (LR-NPC)
Latest Information Update: 28 Jan 2022
At a glance
- Drugs Nimotuzumab (Primary) ; Platinum complexes (Primary)
- Indications Carcinoma; Nasopharyngeal cancer
- Focus Pharmacodynamics
Most Recent Events
- 24 Jan 2022 New trial record
- 25 Nov 2021 Primary endpoint (Overall Survival (OS)) has been not met, according to the results published in the BMC Cancer.